BioVector? 結(jié)核分枝桿菌 H37rv 標(biāo)準(zhǔn)毒株

BioVector? Mycobacterium tuberculosis Strain H37rv Standard Reference Line

第一部分 中文說明

一 產(chǎn)品基本信息與遺傳學(xué)背景

• 菌株名稱：BioVector? Mycobacterium tuberculosis strain H37rv

• 常用別名：H37rv、M.tb H37rv

• 物種來源：結(jié)核分枝桿菌 (Mycobacterium tuberculosis)

• 臨床背景與歷史：H37rv 毒株于 1905 年首次從一名患有慢性肺結(jié)核的患者體內(nèi)分離獲得。經(jīng)過長期的體外傳代與篩選，該菌株因具有穩(wěn)定且完全保留的對人毒力（Fully virulent）特征，被國際醫(yī)學(xué)界及世界衛(wèi)生組織廣泛采納為結(jié)核病研究中最經(jīng)典、應(yīng)用最廣泛的國際通用標(biāo)準(zhǔn)參考毒株。

• 基因組與分子特征：

  • 首個(gè)完成全基因組測序的結(jié)核菌株：其全基因組由約 441 萬個(gè)堿基對（4.41 Mb）組成，GC 含量高達(dá)約 65.6%?；蚪M中包含約 4000 個(gè)復(fù)雜的蛋白質(zhì)編碼基因，其中很大比例專門用于編碼脂質(zhì)代謝相關(guān)的酶，這直接構(gòu)成了其致密、富含分枝菌酸（Mycolic acid）的細(xì)胞壁結(jié)構(gòu)。

  • 完整的毒力島與調(diào)控軸：基因組內(nèi)完整保留了介導(dǎo)對宿主巨噬細(xì)胞入侵、胞內(nèi)寄生及免疫逃逸的核心毒力區(qū)（如 RD1 區(qū)及 ESX-1 分泌系統(tǒng)）。

• 生物安全級別：3級（BSL-3）。由于該菌株屬于對人類具有強(qiáng)致病性的高?？諝鈧鞑ゲ≡w，所有涉及活菌的凍存管復(fù)蘇、擴(kuò)增、離心、分裝及動(dòng)物接種等實(shí)驗(yàn)操作，必須嚴(yán)格在具備國家認(rèn)證資質(zhì)的生物安全三級（BSL-3/P3）實(shí)驗(yàn)室的負(fù)壓生物安全柜內(nèi)進(jìn)行，并強(qiáng)制執(zhí)行雙人雙簽核制度。

二 形態(tài)學(xué)、生長動(dòng)力學(xué)與培養(yǎng)環(huán)境

• 形態(tài)學(xué)特征：

  • 微觀形態(tài)：經(jīng)抗酸染色（Acid-fast staining/齊爾-尼爾森染色）后，在顯微鏡下展現(xiàn)為特異性的紅染、纖細(xì)、略微彎曲的桿菌，通常呈現(xiàn)出由索狀因子（Cord factor）介導(dǎo)的平行排列或特征性“索狀結(jié)構(gòu)”（Cord-like growth formations）。

  • 宏觀菌落形態(tài)：在固體培養(yǎng)基（如羅氏培養(yǎng)基）上生長數(shù)周后，形成典型的干燥、粗糙、微黃或呈乳白色、表面如菜花狀（Vrucous/Cauliflower-like）的特征性菌落。

• 生長模式：在含有吐溫-80（Tween-80）等非離子表面活性劑的液體培養(yǎng)基中呈均一分散懸浮生長；在不含去污劑的培養(yǎng)基中則高度傾向于在液面自發(fā)聚集成致密的菌膜（Pellicle）。

• 群體增殖動(dòng)力學(xué)：屬于典型的極慢速生長菌，其群體對數(shù)增長倍增時(shí)間大約為 18 至 24 小時(shí)。

• 標(biāo)準(zhǔn)完全培養(yǎng)基配方：

  • 固體培養(yǎng)基（L-J 羅氏培養(yǎng)基）：基于新鮮全蛋液、馬鈴薯粉、甘油及孔雀綠等成分混合滅菌而成的經(jīng)典凝固斜面。

  • 液體培養(yǎng)基（7H9 / 7H11 基礎(chǔ)系列）：

    • BioVector? Middlebrook 7H9 液體基礎(chǔ)成分。

    • 維持添加：10% 優(yōu)質(zhì) ADC 或 OADC 生長增強(qiáng)添加劑（含牛血清白蛋白、右旋糖、過氧化氫酶及油酸）。

    • 防聚集添加：0.05% 至 0.1% 吐溫-80（Tween-80）或泰洛沙泊（Tyloxapol），用以打散索狀聚集物，確保光度法測定菌密度的準(zhǔn)確性。

    • 0.2% 甘油（Glycerol）。

• 物理培養(yǎng)參數(shù)：37攝氏度恒溫恒濕、避光靜置培養(yǎng)。因其為專性需氧菌，液體擴(kuò)增時(shí)需保持足夠的瓶內(nèi)頂空體積（建議液量不超過瓶容積的 20%）。

三 菌株常規(guī)傳代與凍存標(biāo)準(zhǔn)操作步驟

1. 固體到液體擴(kuò)增轉(zhuǎn)種操作（Subculturing Protocol）：

   • 菌苔收集：在 BSL-3 負(fù)壓柜內(nèi)，使用無菌接種環(huán)輕輕刮取 L-J 斜面上生長旺盛的干燥 H37rv 菌苔（盡量避免刮入底層培養(yǎng)基）。

   • 機(jī)械打散與洗滌：將菌苔置于含有無菌生理鹽水或 7H9 基礎(chǔ)液的小離心管中，加入無菌玻璃微珠，在渦旋振蕩器上劇烈震蕩 1 到 2 分鐘，以物理研磨方式切斷索狀因子，使菌塊充分打散成單菌懸液。靜置 10 分鐘讓大顆粒沉降。

   • 接種參數(shù)：吸取上層均勻的單菌懸液，按 1比10 到 1比20 的稀釋比例接種入含有 OADC 和 吐溫-80 的 7H9 液體培養(yǎng)基中。初始起始濁度控制在波長 600 nm 下光密度值（OD600）為 0.05 至 0.1 之間。通常需要靜置或低速搖床（100 rpm）孵育 2 到 3 周 才能進(jìn)入對數(shù)生長旺盛期（OD600 達(dá)到 0.6 至 1.0）。

2. 菌種凍存保藏：

   • 當(dāng)液體培養(yǎng)物達(dá)到對數(shù)中期（OD600 約 0.5-0.8）時(shí)，直接加入甘油作為低溫保護(hù)劑，使其最終工作濃度達(dá)到 15% 至 20%。

   • 徹底混勻后，分裝入耐高壓耐低溫的螺口凍存管中。將其放入梯度降溫盒中進(jìn)行程序降溫，隨后移入 負(fù)80攝氏度超低溫冰箱或液氮罐 vapor phase 中長期鎖定保藏。

四 核心科研應(yīng)用方向

1. 抗結(jié)核新藥與高通量小分子抗生素體外篩選（Drug Screening）：BioVector? H37rv 作為國際公認(rèn)的標(biāo)準(zhǔn)敏感株，廣泛用作陽性對照和靶向底物。通過測定最低抑菌濃度（MIC）和最低殺菌濃度（MBC），來評估全新機(jī)制的小分子候選藥物（如針對 MmpL3、AtpE 等核心靶點(diǎn)）以及中草藥提取物的體外殺菌效能。

2. 耐藥機(jī)制演變與交叉耐藥屏障評估：常通過將 H37rv 長期暴露于遞增濃度的抗結(jié)核藥物（如異煙肼、利福平、乙胺丁醇等）環(huán)境中，進(jìn)行體外人工定向耐藥株演變實(shí)驗(yàn)。以此模擬臨床多耐藥（MDR）或廣泛耐藥（XDR）突變株的產(chǎn)生，進(jìn)而通過全基因組重測序鎖定新的耐藥基因位點(diǎn)。

3. 新型結(jié)核疫苗、佐劑及免疫原性評價(jià)模型（Vaccine Evaluation）：作為經(jīng)典強(qiáng)毒攻擊株（Challenge strain）。通過對實(shí)驗(yàn)動(dòng)物（如 C57BL/6 小鼠、豚鼠）接種各種新型候選疫苗（如亞單位疫苗、重組 BCG、DNA 疫苗等）后，在 BSL-3 設(shè)施內(nèi)使用 H37rv 進(jìn)行氣溶膠或尾靜脈強(qiáng)毒攻擊。通過檢測動(dòng)物肺、脾臟內(nèi)的荷菌量（CFU 計(jì)數(shù)）和組織病理學(xué)變化，來權(quán)威量化評估疫苗的體內(nèi)免疫保護(hù)效力。

4. 結(jié)核分枝桿菌宿主-病原體交互機(jī)制（Host-Pathogen Interactions）解析：在體外細(xì)胞模型中，常用 H37rv 感染人類原代巨噬細(xì)胞、THP-1 分化細(xì)胞或非小細(xì)胞肺癌細(xì)胞（如 A549），用以研究結(jié)核菌如何阻止吞噬體與溶酶體融合、抑制宿主細(xì)胞凋亡、誘導(dǎo)壞死以及啟動(dòng)肉芽腫（Granuloma）早期核心形成的精細(xì)分子網(wǎng)絡(luò)。

PART 2 ENGLISH SECTION

I General Information and Genetic Background

• Strain Name: BioVector? Mycobacterium tuberculosis strain H37rv

• Synonyms: H37rv, M.tb H37rv

• Species Origin: Mycobacterium tuberculosis

• Clinical History & Origin: Isolated in 1905 from a human patient presenting with chronic pulmonary tuberculosis. Following long-term systematic in vitro passaging configurations, this line was globally adopted as the definitive standard virulent reference strain by academic consortia and the World Health Organization due to its stable, fully intact, reproducible virulence replication kinetics.

• Genome & Molecular Features:

  • Pioneering Reference Sequenced Strain: Possesses a circular genome of approximately 4.41 million base pairs (4.41 Mb) with a remarkably high GC content averaging 65.6%. It hosts around 4000 distinct protein-coding sequences, dedicating a high metabolic percentage to lipid synthesis enzymes that construct its dense, mycolic acid-rich hydrophobic cell envelope.

  • Preserved Virulence Architecture: Intact containment of crucial pathogenicity clusters, including the Region of Difference 1 (RD1) and the specialized ESX-1 (Type VII) secretion machine required for subverting host intracellular defenses.

• Biosafety Level: Biosafety Level 3 (BSL-3). As a high-risk airborne human pathogen capable of causing severe respiratory and systemic disease, all manipulation stages involving viable bacteria—including vial thawing, active propagation, harvesting, and mock challenges—must strictly take place inside certified BSL-3 isolation facilities utilizing negative-pressure biosafety enclosures under dual-operator authentication.

II Morphological Attributes, Kinetic Profiles, and Cultivation Media

• Morphology:

  • Microscopic View: Exhibits strong red staining under classical acid-fast coloration matrices (e.g., Ziehl-Neelsen stain). Cells appear under oil immersion as slender, slightly curved rods organized in characteristic parallel lines or serpentine "cord-like growth formations" directed by the surface lipid cord factor.

  • Macroscopic Colonial Traits: Produces dry, rough, off-white to cream-colored colonies presenting a classical verrucous or cauliflower-like topography on solid media slants after multi-week incubation steps.

• Growth Mode: Spreads as a homogenous suspension configuration inside fluid broths supplemented with non-ionic detergents; readily constructs dense, tough floating surface pellicles on un-supplemented fluid layers.

• Population Doubling Kinetics: Categorized as an obligate slow-growing bacterium. Its typical logarithmic doubling phase spans an average sequence of 18 to 24 hours.

• Standard Complete Medium Specifications:

  • Solid Matrix (L?wenstein-Jensen / L-J Slants): Coagulated egg-based medium formulations incorporated with potato flour, glycerol, and malachite green.

  • Liquid Matrix (Middlebrook 7H9 / 7H11 Series):

    • BioVector? Middlebrook 7H9 liquid basal backbone broth.

    • Routine Supplements: 10% premium ADC or OADC enrichment supplement cocktail (bovine serum albumin, dextrose, catalase, and oleic acid).

    • Anti-Clumping Additives: 0.05% to 0.1% Tween-80 or Tyloxapol to structurally break up serpentine cords, establishing precise optical density tracking.

    • 0.2% Glycerol enrichment.

• Physical Incubation Parameters: Regulated strictly at 37 degrees Celsius under standard humidified conditions in the dark. Being an obligate aerobe, fluid vessels require substantial top-space volumes (fluid configurations should not exceed 20% of the overall bottle displacement).

III Routine Passaging and Cryopreservation Protocols

1. Solid Slant to Fluid Broth Subculturing Routine:

   • Biomass Harvesting: Inside a BSL-3 biosafety cabinet, carefully scrape active, young dry colonies from the L-J slant face using a sterile inoculation loop, avoiding core agar fragments.

   • Mechanical Homogenization: Deposit the harvested biomass into a sterile vial carrying 7H9 base media alongside sterile glass micro-beads. Vortex dynamically for 1 to 2 minutes to physically break up cell clumps and resolve the serpentine cord architectures into a uniform suspension. Allow larger residues to settle for 10 minutes.

   • Inoculation Seeding: Siphon off the homogenous top fluid and introduce it into fresh OADC-Tween-80 supplemented 7H9 liquid parameters at split ratios ranging from 1:10 to 1:20. Balance the starting optical density to an OD600 metric between 0.05 and 0.1. Incubate statically or under low-speed orbital agitation (100 rpm) for 2 to 3 weeks to safely reach peak mid-logarithmic density (OD600 around 0.6-1.0).

2. Cryovial Stock Preservation:

   • Once the expanding fluid culture achieves optimal mid-logarithmic parameters (OD600 spanning 0.5-0.8), incorporate sterile glycerol directly as a cryoprotectant to settle at a final configuration of 15% to 20% total volume.

   • Mix thoroughly, distribute into high-pressure leak-proof internal thread cryovials, and place inside standard temperature-gradient freeze boxes. Lower the temperature progressively to -80 degrees Celsius before moving stocks into liquid nitrogen vapor phase repositories for long-term secure lock-down.

IV Strategic Research Applications

1. High-Throughput Anti-Tubercular Drug Discovery and Antibiotic Profiling: BioVector? H37rv serves as the definitive global drug-susceptible standard benchmark. It is deployed to run automated high-throughput assays evaluating candidate chemical arrays and natural botanicals, indexing precise Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) data.

2. Directed In Vitro Resistant Evolution Mapping: Routinely exposed to incremental selective pressures of frontline compounds (such as Isoniazid, Rifampicin, or Ethambutol) to evolve multi-drug resistant (MDR) variants in vitro. Whole-genome re-sequencing of the derived lines tracks novel single-nucleotide polymorphisms mapping drug-target escape routes.

3. In Vivo Efficacy Testing of Candidate Vaccines and Novel Adjuvants: Serves as the premier virulent choice for challenge assays. Following immunization regimens with candidate vaccines (e.g., recombinant BCG, subunits, or DNA platforms) on model species (C57BL/6 mice, guinea pigs), subjects are exposed to H37rv virulent aerogenic aerosol challenges within BSL-3 facilities. Colony Forming Unit (CFU) counts from lung and spleen homogenized extracts index protective performance.

4. Dissecting Host-Pathogen Interaction Topologies: Used in cell culture assays to infect primary human alveolar macrophages, differentiated THP-1 lineages, or lung epithelial lines (A549). These screens elucidate how virulent Mycobacterium tuberculosis disrupts phagosome-lysosome fusion architectures, down-regulates apoptotic executioners, and initializes the basic transcriptomic pathways of early-stage granuloma synthesis.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址http://www.nedfriskphoto.com